Funds › Farallon Capital Management, LLC
Farallon Capital Management, LLC
13F for Q2 2026, filed Aug 14, 2026. 82 positions worth $21.7B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$21.7B
+$2.6B (13.7%) vs Q1 2026
Positions
82
168 in Q1 2026
Top 10 share
43.9%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Farallon Capital Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Farallon Capital Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Farallon Capital Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | RVMD Revolution Medicines, Inc. | 13.55M | $2.5B | 11.7% | -0.4% | 13F ↗ |
| 2 | Electronic Arts Inc | 7.92M | $1.6B | 7.5% | +6.0% | 13F ↗ |
| 3 | BBIO BridgeBio Pharma, Inc. | 10.74M | $800.1M | 3.7% | +14.7% | 13F ↗ |
| 4 | PTGX Protagonist Therapeutics, Inc. | 6.35M | $778.2M | 3.6% | Unchanged | 13F ↗ |
| 5 | EXEL Exelixis, Inc. | 13.47M | $732.8M | 3.4% | +2.7% | 13F ↗ |
| 6 | LQDA Liquidia Corporation | 8.37M | $666.9M | 3.1% | -3.4% | 13F ↗ |
| 7 | AMZN Amazon.com, Inc. | 2.63M | $627.5M | 2.9% | -37.6% | 13F ↗ |
| 8 | LNTH Lantheus Holdings, Inc. · Commonstock | 5.58M | $619.4M | 2.9% | Unchanged | 13F ↗ |
| 9 | NTRA Natera, Inc. | 2.22M | $602.2M | 2.8% | -30.8% | 13F ↗ |
| 10 | UNH UnitedHealth Group Incorporated | 1.27M | $528.1M | 2.4% | -30.3% | 13F ↗ |
| 11 | TMO Thermo Fisher Scientific Inc | 1.05M | $526.0M | 2.4% | +19.0% | 13F ↗ |
| 12 | ROIV Roivant Sciences Ltd. | 14.31M | $506.4M | 2.3% | +47.9% | 13F ↗ |
| 13 | AON Aon plc | 1.38M | $458.6M | 2.1% | -45.0% | 13F ↗ |
| 14 | BSX Boston Scientific Corporation | 10.52M | $449.0M | 2.1% | +40.8% | 13F ↗ |
| 15 | AVGO Broadcom Inc. | 1.15M | $435.1M | 2.0% | -35.3% | 13F ↗ |
| 16 | MSFT Microsoft Corporation | 1.11M | $415.1M | 1.9% | -52.5% | 13F ↗ |
| 17 | TNGX Tango Therapeutics, Inc. | 12.28M | $383.8M | 1.8% | +35.0% | 13F ↗ |
| 18 | KKR KKR & Co. Inc. | 4.12M | $378.0M | 1.7% | -11.8% | 13F ↗ |
| 19 | SNPS Synopsys, Inc. | 829,600 | $370.1M | 1.7% | -31.6% | 13F ↗ |
| 20 | BEAM Beam Therapeutics Inc. | 10.24M | $351.3M | 1.6% | +1.0% | 13F ↗ |
| 21 | Crinetics Pharmaceuticals In | 8.99M | $336.4M | 1.6% | +7.8% | 13F ↗ |
| 22 | GRAL GRAIL, Inc. | 4.16M | $284.1M | 1.3% | +27.9% | 13F ↗ |
| 23 | WAB Westinghouse Air Brake Technologies Corporation | 894,503 | $241.2M | 1.1% | -44.4% | 13F ↗ |
| 24 | IMVT Immunovant, Inc. | 5.80M | $223.7M | 1.0% | +275% | 13F ↗ |
| 25 | TWST Twist Bioscience Corporation | 2.14M | $219.8M | 1.0% | +49.6% | 13F ↗ |
| 26 | AGIO Agios Pharmaceuticals, Inc. | 5.92M | $219.6M | 1.0% | +4.1% | 13F ↗ |
| 27 | ARMK Aramark | 3.63M | $206.3M | 1.0% | -40.9% | 13F ↗ |
| 28 | BIDU Baidu, Inc. · ADR | 1.20M | $137.6M | 0.6% | +171% | 13F ↗ |
| 29 | NVO Novo Nordisk A/S · ADR | 2.62M | $125.6M | 0.6% | +235% | 13F ↗ |
| 30 | ACHC Acadia Healthcare Company, Inc. | 4.22M | $124.6M | 0.6% | +143% | 13F ↗ |
| 31 | BTSG BrightSpring Health Services, Inc. | 1.73M | $120.8M | 0.6% | +7.2% | 13F ↗ |
| 32 | AZN AstraZeneca PLC | 574,000 | $108.8M | 0.5% | +153% | 13F ↗ |
| 33 | JNJ Johnson & Johnson | 408,000 | $103.6M | 0.5% | +176% | 13F ↗ |
| 34 | PBLS Parabilis Medicines, Inc. | 2.37M | $64.8M | 0.3% | New | 13F ↗ |
| 35 | NVS Novartis AG · ADR | 363,000 | $56.9M | 0.3% | New | 13F ↗ |
| 36 | GH Guardant Health, Inc. | 322,200 | $48.3M | 0.2% | +3928% | 13F ↗ |
| 37 | AVTX Avalo Therapeutics, Inc. | 2.50M | $46.2M | 0.2% | +173% | 13F ↗ |
| 38 | JOYY JOYY Inc. · ADR | 699,200 | $46.1M | 0.2% | +20.9% | 13F ↗ |
| 39 | ASMB Assembly Biosciences, Inc. | 1.60M | $44.1M | 0.2% | +30.7% | 13F ↗ |
| 40 | ENTA Enanta Pharmaceuticals, Inc. | 2.42M | $35.3M | 0.2% | -15.8% | 13F ↗ |
| 41 | MAZE Maze Therapeutics, Inc. | 1.11M | $33.1M | 0.2% | +197% | 13F ↗ |
| 42 | MRK Merck & Company, Inc. | 199,000 | $25.6M | 0.1% | -44.9% | 13F ↗ |
| 43 | WRBY Warby Parker Inc. | 828,000 | $25.1M | 0.1% | New | 13F ↗ |
| 44 | FRNM Freenome, Inc. | 2.25M | $24.5M | 0.1% | Unchanged | 13F ↗ |
| 45 | KLRA Kailera Therapeutics, Inc. | 1.10M | $24.2M | 0.1% | New | 13F ↗ |
| 46 | RIO Rio Tinto Plc · ADR | 183,475 | $17.4M | 0.1% | +241% | 13F ↗ |
| 47 | AXTA Axalta Coating Systems Ltd. | 478,000 | $16.4M | 0.1% | New | 13F ↗ |
| 48 | ABVX Abivax SA · ADR | 122,000 | $16.3M | 0.1% | +6000% | 13F ↗ |
| 49 | VNET VNET Group, Inc. · ADR | 1.99M | $16.0M | 0.1% | +220% | 13F ↗ |
| 50 | NTES NetEase, Inc. · ADR | 123,500 | $15.8M | 0.1% | -57.6% | 13F ↗ |
Showing the top 50 of 82 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
18 new, 28 added to, 23 trimmed, 104 exited, 13 unchanged. By estimated dollars.
New positions (18)
| PBLS Parabilis Medicines, Inc. | 2.37M | New | $64.8M |
| NVS Novartis AG · ADR | 363,000 | New | $56.9M |
| WRBY Warby Parker Inc. | 828,000 | New | $25.1M |
| KLRA Kailera Therapeutics, Inc. | 1.10M | New | $24.2M |
| AXTA Axalta Coating Systems Ltd. | 478,000 | New | $16.4M |
| BIIB Biogen Inc. | 71,000 | New | $15.3M |
| TSHA Taysha Gene Therapies, Inc. | 2.25M | New | $15.3M |
| MOBI Mobia Medical, Inc. | 1.13M | New | $15.1M |
| ALMR Alamar Biosciences, Inc. | 462,900 | New | $12.5M |
| IFRX InflaRx N.V. | 3.33M | New | $7.4M |
Added to (28)
| IMVT Immunovant, Inc. | 5.80M | +275% | $164.1M |
| ROIV Roivant Sciences Ltd. | 14.31M | +47.9% | $164.0M |
| BSX Boston Scientific Corporation | 10.52M | +40.8% | $130.2M |
| BBIO BridgeBio Pharma, Inc. | 10.74M | +14.7% | $102.6M |
| TNGX Tango Therapeutics, Inc. | 12.28M | +35.0% | $99.4M |
| Electronic Arts Inc | 7.92M | +6.0% | $92.2M |
| NVO Novo Nordisk A/S · ADR | 2.62M | +235% | $88.1M |
| BIDU Baidu, Inc. · ADR | 1.20M | +171% | $86.9M |
| TMO Thermo Fisher Scientific Inc | 1.05M | +19.0% | $84.1M |
| ACHC Acadia Healthcare Company, Inc. | 4.22M | +143% | $73.4M |
Trimmed (23)
| MSFT Microsoft Corporation | 1.11M | -52.5% | -$459.5M |
| AMZN Amazon.com, Inc. | 2.63M | -37.6% | -$377.9M |
| AON Aon plc | 1.38M | -45.0% | -$374.8M |
| NTRA Natera, Inc. | 2.22M | -30.8% | -$268.5M |
| AVGO Broadcom Inc. | 1.15M | -35.3% | -$237.1M |
| UNH UnitedHealth Group Incorporated | 1.27M | -30.3% | -$229.1M |
| WAB Westinghouse Air Brake Technologies Corporation | 894,503 | -44.4% | -$192.7M |
| SNPS Synopsys, Inc. | 829,600 | -31.6% | -$171.2M |
| ARMK Aramark | 3.63M | -40.9% | -$142.8M |
| KKR KKR & Co. Inc. | 4.12M | -11.8% | -$50.8M |
Exited (104)
| SCHW Charles Schwab Corporation | 3.96M | Exited | -$371.8M |
| GOOG Alphabet Inc. Class C | 996,231 | Exited | -$285.8M |
| V Visa Inc. | 840,710 | Exited | -$254.1M |
| DIS Walt Disney Company | 2.40M | Exited | -$231.5M |
| MA Mastercard Incorporated | 435,071 | Exited | -$217.4M |
| MCK McKesson Corporation | 234,300 | Exited | -$202.8M |
| Centessa Pharmaceuticals plc ADR | 4.81M | Exited | -$191.0M |
| TYRA Tyra Biosciences, Inc. | 3.58M | Exited | -$137.1M |
| THC Tenet Healthcare Corporation | 452,153 | Exited | -$85.3M |
| CAH Cardinal Health, Inc. | 368,000 | Exited | -$77.8M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 13F-HR | 89 | $21.7B | Current | SEC ↗ |
| Q1 2026 | Aug 14, 2026 | 13F-HR/A (new holdings) | 1 | $1.5B | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 172 | $17.5B | Current | SEC ↗ |
| Q4 2025 | Aug 14, 2026 | 13F-HR/A (new holdings) | 1 | $1.0B | Current | SEC ↗ |
| Q4 2025 | May 15, 2026 | 13F-HR/A (new holdings) | 2 | $883.7M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 151 | $21.2B | Current | SEC ↗ |
| Q3 2025 | Feb 17, 2026 | 13F-HR/A (restatement) | 144 | $24.4B | Current | SEC ↗ |
| Q3 2025 | Nov 14, 2025 | 13F-HR | 144 | $24.4B | Replaced | SEC ↗ |
| Q2 2025 | Feb 17, 2026 | 13F-HR/A (new holdings) | 1 | $140.2M | Current | SEC ↗ |
| Q2 2025 | Nov 14, 2025 | 13F-HR/A (new holdings) | 3 | $482.8M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 141 | $23.2B | Current | SEC ↗ |
| Q1 2025 | Feb 17, 2026 | 13F-HR/A (new holdings) | 1 | $273.9M | Current | SEC ↗ |
| Q1 2025 | Nov 14, 2025 | 13F-HR/A (new holdings) | 3 | $416.4M | Current | SEC ↗ |
| Q1 2025 | Aug 14, 2025 | 13F-HR/A (new holdings) | 7 | $2.2B | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 135 | $17.9B | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer